Gray Zone Lymphoma
8
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Amping up With PemJAK
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma